Pharma-Bio Serv, Inc. (PBSV)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 22 | 20 | 19 | 17 | 10 | 9 | 9 | 11 |
| Operating profit | $m | -1 | -0 | ||||||
| Net profit | $m | 2 | -2 | 1 | 1 | -1 | -0 | - | 1 |
| EPS reported | $ | -0.00 | 0.00 | ||||||
| Operating cashflow per share | $ | -0.01 | -15.95 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.01 | -15.95 | ||||||
| Free cash flow | $m | -0 | -305 | ||||||
| Net debt | $m | -11 | -9 | ||||||
| Book value equity | $m | 12 | - | ||||||
| Book value per share | $ | 0.52 | 456.5 | ||||||
| Number of shares | m | 22.96 | 22.91 | ||||||
| DPS (TTM paid) | $ | 0.08 | 0.08 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.04 | 0.00 | ||||||
| P/S LTM | x | 1.38 | 1.31 | ||||||
| P/FCF LTM | x | -55.94 | -0.04 | ||||||
| EV/EBITDA LTM | x | 67.06 | -372.71 | ||||||
| EV/Sales LTM | x | 1.00 | 1.26 | ||||||
| Earnings Yield LTM | % | -0.81% | +0.46% | ||||||
| FCF Yield | % | -1.79% | -2457.6% | ||||||
| Quality | |||||||||
| ROE | % | -0.84% | +0.00% | ||||||
| ROIC | % | -5.34% | -0.00% | ||||||
| Operating margin | % | -7.08% | -4.36% | ||||||
| Gross margin | % | +32.33% | +32.35% | ||||||
| FCF/Sales | % | -2.46% | -4008.4% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -5.34% | -0.27% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +13.88% | +12.93% | ||||||
| Dividend Growth | % | 0.00% | 0.00% | ||||||
| Payout Ratio | % | -1702.7% | -40.81% | ||||||
| FCF/Debt | x | -7.68 | - | ||||||
| Net Debt/EBITDA | x | -24.85 | 15.32 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -0.91 | - | ||||||
| Gross debt/equity | x | 0.00 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Pharma-Bio Serv, Inc. functions as a specialized consulting firm, providing services focused on regulatory compliance and the transfer of technology. The company offers its compliance expertise to a diverse range of clients, including those in the pharmaceutical, chemical, biotechnology, medical device, cosmetic, and food industries, as well as related product companies. Its operational reach extends across Puerto Rico, the United States, Europe, and Brazil. The firm's technical advisory offerings encompass vital areas such as regulatory adherence, system validation, technology migration, engineering solutions, comprehensive project management, and ongoing process support. Established in 1993, Pharma-Bio Serv maintains its corporate headquarters in Dorado, Puerto Rico.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Pharma-Bio Serv, Inc. functions as a specialized consulting firm, providing services focused on regulatory compliance and the transfer of technology. The company offers its compliance expertise to a diverse range of clients, including those in the pharmaceutical, chemical, biotechnology, medical device, cosmetic, and food industries, as well as related product companies. Its operational reach extends across Puerto Rico, the United States, Europe, and Brazil. The firm's technical advisory offerings encompass vital areas such as regulatory adherence, system validation, technology migration, engineering solutions, comprehensive project management, and ongoing process support. Established in 1993, Pharma-Bio Serv maintains its corporate headquarters in Dorado, Puerto Rico.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free